Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC-921 in Advanced Malignant Solid Tumors
NCT07824934Phase 1Recruiting
- Sponsor
- Sunshine Lake Pharma
- Start
- Sep 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of HEC-921 in solid tumor, colon adenocarcinoma and rectal adenocarcinoma (2 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Dose-Limiting Toxicity at 21 days and Incidence and severity of adverse events and serious adverse events at 1 year. Started Sep 2026; status: recruiting.
02
Drugs
HEC-921
03
Conditions
solid tumorcolon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on NCT07824934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07824934.